Systemic administration of VEGF antagonists has also been associated with many adverse effects, such as increased bleeding, cardiovascular events, delayed wound healing, and gastrointestinal issues, stemming from the interrelationship between antiangiogenic therapy and tumor microenvironments [31]. The gene discussed is VEGFA; the disease is neoplasm.